Axogen, Inc. Reports 2021 Fourth Quarter and Full-Year Financial Results
Axogen, Inc. (NASDAQ: AXGN) reported Q4 and full-year 2021 financial results, showing a 3% decline in Q4 revenue at $31.5 million compared to Q4 2020. Full-year revenue rose 13% to $127.4 million.
The adjusted net loss for Q4 stood at $3.3 million, unchanged from the previous year, while the gross margin was 82.8%. The company anticipates 2022 revenue between $135 million and $142 million, projecting growth of 10% to 15% over 2021.
- Full-year revenue increased by 13% to $127.4 million.
- Gross margin improved to 82.0% for 2021 from 80.8% in 2020.
- Core Accounts increased by 9% to 294, indicating growth in established accounts.
- Management expects 2022 revenue growth of 10% to 15% over 2021.
- Q4 revenue decreased by 3% compared to Q4 2020.
- Adjusted EBITDA loss worsened to $1.7 million in Q4 2021 from $1.3 million in Q4 2020.
- Cash reserves fell to $90.3 million, down from $98.1 million.
ALACHUA, Fla. and TAMPA, Fla., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2021.
Fourth Quarter 2021 and Business Highlights
- Net revenue was
$31.5 million during the fourth quarter, a3% decrease compared to fourth-quarter 2020 revenue of$32.5 million . - Fourth quarter revenue includes
$0.5 million from the reversal of a sales return reserve recorded in the second quarter of 2021 for Avive® Soft Tissue Membrane, for which the company voluntarily suspended market availability on June 1, 2021. Avive revenue in the fourth quarter of 2020 was approximately$1.6 million . - Gross margin was
82.8% for the quarter compared to83.2% in the fourth quarter of 2020. - Adjusted net loss was
$3.3 million for the quarter, or$0.08 per share, for both the fourth quarter of 2021 and 2020. - Adjusted EBITDA loss was
$1.7 million for the quarter, compared to an adjusted EBITDA loss of$1.3 million in the fourth quarter of 2020. - The balance of all cash, cash equivalents, and investments on December 31, 2021 was
$90.3 million , compared to a balance of$98.1 million on September 30, 2021. The net change includes capital expenditures of$5.8 million related to the construction of our new processing facility in Dayton, OH, and$1.9 million of operating cash burn in the quarter. - Core Accounts as of December 31, 2021 were 294, a
9% increase compared to 269 as of December 31, 2020. Revenue from Core Accounts continued to represent approximately60% of total revenue. - Active Accounts as of December 31, 2021 were 951, a
6% increase from 893 as of December 31, 2020. Revenue from the top10% of Active Accounts continued to represent approximately35% of total revenue.
“I am pleased with our full-year results in light of a difficult operating environment in the second half of the year,” commented Karen Zaderej, chairman, CEO, and president of Axogen, Inc. “We believe more surgeons and accounts are recognizing the value Axogen provides, and we enter 2022 with a strong commercial organization and a solid foundation of clinical evidence. We look forward to the release of the topline results of our RECON study in the second quarter and returning to a more normalized growth environment through the year.”
Full-Year 2021 Financial Results and Business Highlights
- Full-year 2021 revenue was
$127.4 million , a13% increase compared to 2020 revenue of$112.3 million . - Avive revenue totaled approximately
$4.1 million and$5.5 million for the years ended 2021 and 2020, respectively. - Gross margin was
82.0% for the full year, compared to80.8% in 2020. - Adjusted net loss was
$13.7 million for the full year, or$0.33 per share, compared to$15.3 million , or$0.38 per share, in 2020. - Adjusted EBITDA loss was
$6.7 million for the full year, compared to an adjusted EBITDA loss of$11.1 million in 2020. - Ended the year with 115 direct sales representatives, compared to 111 at the end of 2020.
- Ended the year with 181 peer-reviewed clinical publications featuring Axogen’s nerve repair product portfolio.
2022 Financial Guidance
Management expects 2022 revenue will be in the range of
Conference Call
The Company will host a conference call and webcast for the investment community today at 4:30 p.m. ET. Investors interested in participating by phone are invited to call toll free at 1-877-407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company's website at www.axogeninc.com and clicking on the webcast link.
Following the conference call, a replay will be available in the Investors section of the company's website at www.axogeninc.com under Investors.
About the RECON Clinical Study
RECON is a multicenter, prospective, randomized, subject and evaluator blinded comparative clinical study of nerve cuffs (manufactured conduits) and Avance® Nerve Graft, evaluating recovery outcomes for the repair of nerve discontinuities. The phase 3 pivotal study is designed to test for non-inferiority between the static two-point discrimination outcomes for Avance Nerve Graft and manufactured conduit. The study design also allows for a sequential test for superiority of Avance Nerve Graft, following the non-inferiority analysis.
About Axogen
Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Cautionary Statements Concerning Forward-Looking Statements
This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements related to the impact of COVID-19 on our business, hospital staffing challenges and its impact on our business, statements regarding our growth, our financial guidance and performance, product development, product potential, regulatory process and approvals, APC renovation timing and expense, sales growth, product adoption, market awareness of our products, anticipated capital requirements, including the potential of future financings, data validation, expected clinical study enrollment, timing and outcomes, our assessment of our internal controls over financial reporting, our visibility at and sponsorship of conferences and our educational events, regulatory process and approvals and other factors, including legislative, regulatory, political and economic developments not within our control. The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect our business and our market, particularly those risk factors described under Part I, Item 1A., “Risk Factors,” of our Annual Report on Form 10-K for the most recently ended fiscal year, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise
Contact:
Axogen, Inc.
Ed Joyce, Director, Investor Relations
ejoyce@axogeninc.com
InvestorRelations@axogeninc.com
| AXOGEN, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (unaudited) | ||||||||
| (In Thousands, Except Share and Per Share Amounts) | ||||||||
| December 31, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 32,756 | $ | 48,767 | ||||
| Restricted cash | 6,251 | 6,842 | ||||||
| Investments | 51,330 | 55,199 | ||||||
| Accounts receivable, net | 18,158 | 17,618 | ||||||
| Inventory | 16,693 | 12,529 | ||||||
| Prepaid expenses and other | 1,861 | 4,296 | ||||||
| Total current assets | 127,049 | 145,251 | ||||||
| Property and equipment, net | 62,881 | 38,398 | ||||||
| Operating lease right-of-use assets | 15,193 | 15,614 | ||||||
| Finance lease right-of-use assets | 42 | 64 | ||||||
| Intangible assets, net | 2,859 | 2,054 | ||||||
| Total assets | $ | 208,024 | $ | 201,381 | ||||
| Liabilities and shareholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 22,459 | $ | 21,968 | ||||
| Current maturities of long-term lease obligations | 1,834 | 863 | ||||||
| Total current liabilities | 24,293 | 22,831 | ||||||
| Long-term debt, net of financing fees | 44,821 | 32,027 | ||||||
| Debt derivative liabilities | 5,562 | 2,497 | ||||||
| Long-term lease obligations | 20,798 | 20,874 | ||||||
| Other long-term liabilities | — | 3 | ||||||
| Total liabilities | 95,474 | 78,232 | ||||||
| Shareholders’ equity: | ||||||||
| Common stock, $.01 par value per share; 100,000,000 shares authorized | 417 | 406 | ||||||
| Additional paid-in capital | 342,765 | 326,390 | ||||||
| Accumulated deficit | (230,632 | ) | (203,647 | ) | ||||
| Total shareholders’ equity | 112,550 | 123,149 | ||||||
| Total liabilities and shareholders' equity | $ | 208,024 | $ | 201,381 | ||||
| AXOGEN, INC. | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| Three Months and Years Ended December 31, 2021 and 2020 | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| (In Thousands, Except Per Share Amounts) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | December 31, | December 31, | |||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenues | $ | 31,537 | $ | 32,495 | $ | 127,358 | $ | 112,300 | ||||||||
| Cost of goods sold | 5,428 | 5,463 | 22,931 | 21,581 | ||||||||||||
| Gross profit | 26,109 | 27,032 | 104,427 | 90,719 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Sales and marketing | 17,734 | 19,805 | 73,328 | 69,659 | ||||||||||||
| Research and development | 6,302 | 4,931 | 24,177 | 17,846 | ||||||||||||
| General and administrative | 7,426 | 7,670 | 32,338 | 26,396 | ||||||||||||
| Total costs and expenses | 31,462 | 32,406 | 129,843 | 113,901 | ||||||||||||
| Loss from operations | (5,353 | ) | (5,374 | ) | (25,416 | ) | (23,182 | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Investment income | 13 | 29 | 93 | 605 | ||||||||||||
| Interest expense | 71 | (595 | ) | (1,356 | ) | (1,054 | ) | |||||||||
| Change in fair value of derivatives | 124 | (46 | ) | (28 | ) | (117 | ) | |||||||||
| Other expense | (141 | ) | (24 | ) | (278 | ) | (38 | ) | ||||||||
| Total other (expense) income, net | 67 | (636 | ) | (1,569 | ) | (604 | ) | |||||||||
| Net loss | $ | (5,286 | ) | $ | (6,010 | ) | $ | (26,985 | ) | $ | (23,786 | ) | ||||
| Weighted average common shares outstanding – basic and diluted | 41,593 | 40,246 | 41,215 | 39,967 | ||||||||||||
| Loss per common share – basic and diluted | $ | (0.13 | ) | $ | (0.15 | ) | $ | (0.65 | ) | $ | (0.60 | ) | ||||
| Adjusted net loss - non GAAP | $ | (3,272 | ) | $ | (3,265 | ) | $ | (13,697 | ) | $ | (15,281 | ) | ||||
| Adjusted loss per common share – basic and diluted | $ | (0.08 | ) | $ | (0.08 | ) | $ | (0.33 | ) | $ | (0.38 | ) | ||||
| AXOGEN, INC. | ||||||||||||||||
| RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES | ||||||||||||||||
| Three Months and Years Ended December 31, 2021 and 2020 | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| (In Thousands, Except Per Share Amounts) | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| December 31, | December 31, | December 31, | December 31, | |||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Gross profit | $ | 26,109 | $ | 27,032 | $ | 104,427 | $ | 90,719 | ||||||||
| Avive inventory write-down and production costs | - | - | 1,429 | - | ||||||||||||
| Adjusted gross profit | $ | 26,109 | $ | 27,032 | $ | 105,856 | $ | 90,719 | ||||||||
| Net loss | $ | (5,286 | ) | $ | (6,010 | ) | $ | (26,985 | ) | $ | (23,786 | ) | ||||
| Depreciation and amortization expense | 1,563 | 1,284 | (1) | 5,572 | 3,692 | |||||||||||
| Investment income | (13 | ) | (29 | ) | (93 | ) | (605 | ) | ||||||||
| Income tax expense | 138 | 77 | 205 | 77 | ||||||||||||
| Interest expense | (71 | ) | 595 | 1,356 | 1,054 | |||||||||||
| EBITDA - non GAAP | $ | (3,669 | ) | $ | (4,083 | ) | (1) | $ | (19,945 | ) | $ | (19,568 | ) | |||
| Non cash stock-based compensation expense | 1,509 | 2,745 | 10,919 | 8,470 | ||||||||||||
| Litigation and related costs | 505 | — | 2,369 | 35 | ||||||||||||
| Adjusted EBITDA - non GAAP | $ | (1,655 | ) | $ | (1,338 | ) | (1) | $ | (6,657 | ) | $ | (11,063 | ) | |||
| Net loss | $ | (5,286 | ) | $ | (6,010 | ) | $ | (26,985 | ) | $ | (23,786 | ) | ||||
| Non cash stock-based compensation expense | 1,509 | 2,745 | 10,919 | 8,470 | ||||||||||||
| Litigation and related costs | 505 | — | 2,369 | 35 | ||||||||||||
| Adjusted net loss - non GAAP | $ | (3,272 | ) | $ | (3,265 | ) | $ | (13,697 | ) | $ | (15,281 | ) | ||||
| Weighted average common shares outstanding – basic and diluted | 41,593 | 40,246 | 41,215 | 39,967 | ||||||||||||
| Adjusted loss per common share – basic and diluted | $ | (0.08 | ) | $ | (0.08 | ) | $ | (0.33 | ) | $ | (0.38 | ) | ||||
| (1) The Company has revised its definition of EBITDA and Adjusted EBITDA to include amortization of its right-of-use assets and amortization of debt discount and deferred financing fees. See Reconciliation of Revised EBITDA, Adjusted EBITDA, and Depreciation and Amortization. | ||||||||||||||||
| AXOGEN, INC. | |||||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY | |||||||||||||||||||
| Three Months and Years Ended December 31, 2021 and 2020 | |||||||||||||||||||
| (unaudited) | |||||||||||||||||||
| (In Thousands) | |||||||||||||||||||
| Common Stock | Total | ||||||||||||||||||
| Shares | Amount | Additional Paid- in Capital | Accumulated Deficit | Shareholders' Equity | |||||||||||||||
| For the Three Months Ended December 31, 2021: | |||||||||||||||||||
| Balance at September 30, 2021 | 41,559 | $ | 415 | $ | 340,212 | $ | (225,346 | ) | $ | 115,281 | |||||||||
| Net loss | - | - | - | (5,286 | ) | (5,286 | ) | ||||||||||||
| Stock-based compensation | - | - | 1,509 | - | 1,509 | ||||||||||||||
| Issuance of restricted and performance stock units | 48 | - | - | - | - | ||||||||||||||
| Exercise of stock options and employee stock purchase plan | 130 | 2 | 1,044 | - | 1,046 | ||||||||||||||
| Balance at December 31, 2021 | 41,737 | $ | 417 | $ | 342,765 | $ | (230,632 | ) | $ | 112,550 | |||||||||
| For the Year Ended December 31, 2021: | |||||||||||||||||||
| Balance at December 31, 2020 | 40,619 | $ | 406 | $ | 326,390 | $ | (203,647 | ) | $ | 123,149 | |||||||||
| Net loss | - | - | - | (26,985 | ) | (26,985 | ) | ||||||||||||
| Stock-based compensation | - | - | 10,919 | - | 10,919 | ||||||||||||||
| Issuance of restricted and performance stock units | 254 | 2 | (2 | ) | - | - | |||||||||||||
| Exercise of stock options and employee stock purchase plan | 864 | 9 | 5,458 | - | 5,467 | ||||||||||||||
| Balance at December 31, 2021 | 41,737 | $ | 417 | $ | 342,765 | $ | (230,632 | ) | $ | 112,550 | |||||||||
| For the Three Months Ended December 31, 2020: | |||||||||||||||||||
| Balance at September 30, 2020 | 40,124 | $ | 401 | $ | 318,949 | $ | (197,637 | ) | $ | 121,713 | |||||||||
| Net loss | - | - | - | (6,010 | ) | (6,010 | ) | ||||||||||||
| Stock-based compensation | - | - | 2,745 | - | 2,745 | ||||||||||||||
| Issuance of restricted and performance stock units | 81 | - | - | - | - | ||||||||||||||
| Shares surrendered by employees to pay tax withholdings | (2 | ) | 1 | (6 | ) | - | (5 | ) | |||||||||||
| Exercise of stock options and employee stock purchase plan | 168 | 2 | 1,022 | - | 1,024 | ||||||||||||||
| Exercise of Oberland option, net of settlement | 248 | 2 | 3,680 | - | 3,682 | ||||||||||||||
| Balance at December 31, 2020 | 40,619 | $ | 406 | $ | 326,390 | $ | (203,647 | ) | $ | 123,149 | |||||||||
| For the Year Ended December 31, 2020: | |||||||||||||||||||
| Balance at December 31, 2019 | 39,590 | $ | 396 | $ | 311,618 | $ | (179,861 | ) | $ | 132,153 | |||||||||
| Net loss | - | - | - | (23,786 | ) | (23,786 | ) | ||||||||||||
| Stock-based compensation | - | - | 8,470 | - | 8,470 | ||||||||||||||
| Issuance of restricted and performance stock units | 249 | 2 | (2 | ) | - | - | |||||||||||||
| Shares surrendered by employees to pay tax withholdings | (40 | ) | - | (670 | ) | - | (670 | ) | |||||||||||
| Exercise of stock options and employee stock purchase plan | 572 | 6 | 3,294 | - | 3,300 | ||||||||||||||
| Exercise of Oberland option, net of settlement | 248 | 2 | 3,680 | - | 3,682 | ||||||||||||||
| Balance at December 31, 2020 | 40,619 | $ | 406 | $ | 326,390 | $ | (203,647 | ) | $ | 123,149 | |||||||||
| AXOGEN, INC. | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| Years Ended December 31, 2021 and 2020 | ||||||||
| (unaudited) | ||||||||
| (In Thousands) | ||||||||
| Year Ended | ||||||||
| December 31, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (26,985 | ) | $ | (23,786 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 2,721 | 1,507 | ||||||
| Amortization of right-of-use assets | 1,818 | 1,800 | ||||||
| Amortization of intangible assets | 202 | 153 | ||||||
| Amortization of debt discount and deferred financing fees | 831 | 232 | ||||||
| Loss on disposal of equipment | - | 3 | ||||||
| Provision for bad debt | (41 | ) | (105 | ) | ||||
| Provision for inventory write-down | 3,314 | 2,242 | ||||||
| Change in fair value of deriviatives | 28 | 117 | ||||||
| Investment (gains) losses | 68 | (47 | ) | |||||
| Stock-based compensation | 10,919 | 8,470 | ||||||
| Change in operating assets and liabilities: | ||||||||
| Accounts receivable | (499 | ) | (635 | ) | ||||
| Inventory | (7,478 | ) | (910 | ) | ||||
| Prepaid expenses and other | 2,435 | (2,524 | ) | |||||
| Accounts payable and accrued expenses | (270 | ) | 4,958 | |||||
| Operating lease obligations | (463 | ) | (1,086 | ) | ||||
| Cash paid for interest portion of finance leases | (2 | ) | (3 | ) | ||||
| Contract and other liabilities | (3 | ) | (12 | ) | ||||
| Net cash used in operating activities | (13,405 | ) | (9,626 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchase of property and equipment | (27,811 | ) | (21,905 | ) | ||||
| Economic development grant proceeds | 950 | — | ||||||
| Purchase of investments | (68,699 | ) | (77,806 | ) | ||||
| Proceeds from sale of investments | 72,500 | 83,440 | ||||||
| Cash payments for intangible assets | (589 | ) | (692 | ) | ||||
| Net cash used in investing activities | (23,649 | ) | (16,963 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of long-term debt | 15,000 | 35,000 | ||||||
| Proceeds from the paycheck protection program loan | — | 7,820 | ||||||
| Repayment of the paycheck protection program loan | — | (7,820 | ) | |||||
| Proceeds from issuance of common stock | — | 3,500 | ||||||
| Payments for debt issuance costs | — | (642 | ) | |||||
| Payments of employee tax withholding in exchange of common stock awards | — | (670 | ) | |||||
| Cash paid for debt portion of finance leases | (15 | ) | (14 | ) | ||||
| Proceeds from exercise of stock options and ESPP stock purchases | 5,467 | 3,300 | ||||||
| Net cash provided by financing activities | 20,452 | 40,474 | ||||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | (16,602 | ) | 13,885 | |||||
| Cash, cash equivalents and restricted cash, beginning of period | 55,609 | 41,724 | ||||||
| Cash, cash equivalents and restricted cash, end of period | $ | 39,007 | $ | 55,609 | ||||
| Supplemental disclosures of cash flow activity: | ||||||||
| Cash paid for interest, net of capitalized interest | $ | 495 | $ | 822 | ||||
| Supplemental disclosure of non-cash investing and financing activities | ||||||||
| Acquisition of fixed assets in accounts payable and accrued expenses | $ | 1,420 | $ | 1,077 | ||||
| Obtaining a right-of-use asset in exchange for a lease liability | $ | 1,375 | $ | 14,259 | ||||
| Acquisition of leasehold asset | $ | - | $ | 5,250 | ||||
| Embedded derivative associated with the long-term debt | $ | 3,037 | $ | 2,563 | ||||
| Acquisition of intangible assets in accounts payable and accrued expenses | $ | 418 | $ | - | ||||
| Conversion of the Oberland option | $ | - | $ | 182 | ||||
| AXOGEN, INC. | ||||||||||||||||||||
| RECONCILIATION OF REVISED EBITDA, ADJUSTED EBITDA, and DEPRECIATION AND AMORTIZATION | ||||||||||||||||||||
| Three Months Ended September 30, 2021 and 2020; June 30, 2021 and 2020; March 31, 2021 and 2020; December 31, 2020 and | ||||||||||||||||||||
| Year Ended December 31, 2020 | ||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||
| (In Thousands) | ||||||||||||||||||||
| The Company has revised its definition of EBITDA and Adjusted EBITDA to include amortization of its right-of-use assets and amortization of debt discount and deferred financing fees. | ||||||||||||||||||||
| The tables below provide a reconciliation of EBITDA and Adjusted EBITDA as previously reported to the amounts calculated using the new definition. | ||||||||||||||||||||
| Three Months Ended | ||||||||||||||||||||
| March 31, | June 30, | September 30, | ||||||||||||||||||
| 2021 | 2021 | 2021 | ||||||||||||||||||
| Depreciation and amortization expense, as previously reported | $ | 818 | $ | 661 | $ | 706 | ||||||||||||||
| Amortization of ROU assets | 500 | 460 | 458 | |||||||||||||||||
| Amortization of debt discount and deferred financing fees | 112 | 115 | 157 | |||||||||||||||||
| Revised depreciation and amortization expense | $ | 1,430 | $ | 1,236 | $ | 1,321 | ||||||||||||||
| EBITDA - non GAAP, as previously reported | $ | (5,437 | ) | $ | (6,639 | ) | $ | (6,035 | ) | |||||||||||
| Amortization of ROU assets | 500 | 460 | 458 | |||||||||||||||||
| Amortization of debt discount and deferred financing fees | 112 | 115 | 157 | |||||||||||||||||
| Revised EBITDA - non GAAP | $ | (4,825 | ) | $ | (6,064 | ) | $ | (5,420 | ) | |||||||||||
| Adjusted EBITDA - non GAAP, as previously reported | $ | (1,906 | ) | $ | (2,435 | ) | $ | (2,496 | ) | |||||||||||
| Amortization of ROU assets | 500 | 460 | 458 | |||||||||||||||||
| Amortization of debt discount and deferred financing fees | 112 | 115 | 157 | |||||||||||||||||
| Revised Adjusted EBITDA - non GAAP | $ | (1,294 | ) | $ | (1,860 | ) | $ | (1,881 | ) | |||||||||||
| Three Months Ended | Year Ended | |||||||||||||||||||
| March 31, | June 30, | September 30, | December 31, | December 31, | ||||||||||||||||
| 2020 | 2020 | 2020 | 2020 | 2020 | ||||||||||||||||
| Depreciation and amortization expense, as previously reported | $ | 343 | $ | 346 | $ | 439 | $ | 556 | $ | 1,660 | ||||||||||
| Amortization of ROU assets | 470 | 332 | 480 | 518 | 1,800 | |||||||||||||||
| Amortization of debt discount and deferred financing fees | - | - | 22 | 210 | 232 | |||||||||||||||
| Revised depreciation and amortization expense | $ | 813 | $ | 678 | $ | 941 | $ | 1,284 | $ | 3,692 | ||||||||||
| EBITDA - non GAAP, as previously reported | $ | (8,139 | ) | $ | (7,907 | ) | $ | (671 | ) | $ | (4,811 | ) | $ | (21,600 | ) | |||||
| Amortization of ROU assets | 470 | 332 | 480 | 518 | 1,800 | |||||||||||||||
| Amortization of debt discount and deferred financing fees | - | - | 22 | 210 | 232 | |||||||||||||||
| Revised EBITDA - non GAAP | $ | (7,669 | ) | $ | (7,575 | ) | $ | (169 | ) | $ | (4,083 | ) | $ | (19,568 | ) | |||||
| Adjusted EBITDA - non GAAP, as previously reported | $ | (7,583 | ) | $ | (5,685 | ) | $ | 2,276 | $ | (2,066 | ) | $ | (13,095 | ) | ||||||
| Amortization of ROU assets | 470 | 332 | 480 | 518 | 1,800 | |||||||||||||||
| Amortization of debt discount and deferred financing fees | - | - | 22 | 210 | 232 | |||||||||||||||
| Revised Adjusted EBITDA - non GAAP | $ | (7,113 | ) | $ | (5,353 | ) | $ | 2,778 | $ | (1,338 | ) | $ | (11,063 | ) | ||||||
FAQ
What were Axogen's Q4 2021 revenue results?
What is Axogen's revenue guidance for 2022?
How did Axogen perform financially in 2021?
What was Axogen's gross margin for 2021?
